Rituximab Therapy for the Patients With HTLV-1-associated Myelopathy
Who is this study for? Patients with Multiple System Atrophy
What treatments are being studied? Rituximab
Status: Unknown
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Neuroprotective or anti-inflammatory strategies are invaluable in HTLV-1-associated myelopathy due to its rapid progression. We evaluated the efficacy of rituximab in patients with HTLV-1-associated myelopathy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Age 18-80 years
• Patients HTLV-1-associated myelopathy (tropical spastic paraparesis)
Locations
Other Locations
China
Department of Neurology ,First Affiliated Hospital Fujian Medical University
RECRUITING
Fuzhou
Time Frame
Start Date: 2019-08-15
Completion Date: 2024-07
Participants
Target number of participants: 100
Treatments
Experimental: Rituximab group
Rituximab will be administered as 100 mg IV, once per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19 B-cell counts from patients . Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused
No_intervention: Control group
Patients will receive usual care and drug use.
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital of Fujian Medical University